Fuji Pharma Co., Ltd. (4554.T)
JPY 1361.0
(0.29%)
JPY 1361.0
(0.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 26.62 Billion JPY | 26.64% |
| 2022 | 21.02 Billion JPY | 148.41% |
| 2021 | 8.46 Billion JPY | 5579.87% |
| 2020 | 149 Million JPY | -93.84% |
| 2019 | 2.42 Billion JPY | 305.08% |
| 2018 | -1.18 Billion JPY | -84.95% |
| 2017 | -638 Million JPY | -816.85% |
| 2016 | 89 Million JPY | -87.81% |
| 2015 | 730 Million JPY | 353.42% |
| 2014 | 161 Million JPY | -37.11% |
| 2013 | 256 Million JPY | 107.45% |
| 2012 | -3.43 Billion JPY | -17.07% |
| 2011 | -2.93 Billion JPY | -43.87% |
| 2010 | -2.03 Billion JPY | -23.48% |
| 2009 | -1.65 Billion JPY | 9.89% |
| 2008 | -1.83 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 25.93 Billion JPY | 2.86% |
| 2024 Q1 | 25.2 Billion JPY | -5.31% |
| 2024 Q3 | 19.87 Billion JPY | 0.98% |
| 2023 Q2 | 24.4 Billion JPY | -9.0% |
| 2023 Q4 | 26.62 Billion JPY | 3.57% |
| 2023 FY | 26.62 Billion JPY | 26.64% |
| 2023 Q1 | 26.81 Billion JPY | 27.55% |
| 2023 Q3 | 25.7 Billion JPY | 5.35% |
| 2022 Q3 | 20.79 Billion JPY | 3.4% |
| 2022 Q1 | 13.27 Billion JPY | 56.85% |
| 2022 Q2 | 20.11 Billion JPY | 51.52% |
| 2022 FY | 21.02 Billion JPY | 148.41% |
| 2022 Q4 | 21.02 Billion JPY | 1.09% |
| 2021 Q3 | 8.63 Billion JPY | 13.36% |
| 2021 Q1 | 1.51 Billion JPY | 917.45% |
| 2021 FY | 8.46 Billion JPY | 5579.87% |
| 2021 Q4 | 8.46 Billion JPY | -1.96% |
| 2021 Q2 | 7.61 Billion JPY | 402.31% |
| 2020 FY | 149 Million JPY | -93.84% |
| 2020 Q2 | 2.12 Billion JPY | -40.19% |
| 2020 Q3 | 995 Million JPY | -53.22% |
| 2020 Q1 | 3.55 Billion JPY | 46.94% |
| 2020 Q4 | 149 Million JPY | -85.03% |
| 2019 Q2 | 5.15 Billion JPY | 271.72% |
| 2019 Q3 | 3.93 Billion JPY | -23.58% |
| 2019 Q4 | 2.42 Billion JPY | -38.53% |
| 2019 FY | 2.42 Billion JPY | 305.08% |
| 2019 Q1 | 1.38 Billion JPY | 217.46% |
| 2018 FY | -1.18 Billion JPY | -84.95% |
| 2018 Q4 | -1.18 Billion JPY | -147.9% |
| 2018 Q3 | -476 Million JPY | -35.61% |
| 2018 Q2 | -351 Million JPY | -154.93% |
| 2018 Q1 | 639 Million JPY | 200.16% |
| 2017 Q2 | 27 Million JPY | -99.08% |
| 2017 Q1 | 2.94 Billion JPY | 3204.49% |
| 2017 FY | -638 Million JPY | -816.85% |
| 2017 Q4 | -638 Million JPY | 45.93% |
| 2017 Q3 | -1.18 Billion JPY | -4470.37% |
| 2016 Q1 | 3.42 Billion JPY | 369.45% |
| 2016 FY | 89 Million JPY | -87.81% |
| 2016 Q3 | 975 Million JPY | 13.11% |
| 2016 Q4 | 89 Million JPY | -90.87% |
| 2016 Q2 | 862 Million JPY | -74.85% |
| 2015 Q3 | 762 Million JPY | 340.46% |
| 2015 Q2 | 173 Million JPY | -65.54% |
| 2015 Q1 | 502 Million JPY | 211.8% |
| 2015 FY | 730 Million JPY | 353.42% |
| 2015 Q4 | 730 Million JPY | -4.2% |
| 2014 Q2 | 207 Million JPY | -90.45% |
| 2014 Q1 | 2.16 Billion JPY | 746.88% |
| 2014 FY | 161 Million JPY | -37.11% |
| 2014 Q3 | -1.93 Billion JPY | -1036.23% |
| 2014 Q4 | 161 Million JPY | 108.31% |
| 2013 FY | 256 Million JPY | 107.45% |
| 2013 Q1 | 2.2 Billion JPY | 164.18% |
| 2013 Q4 | 256 Million JPY | -87.14% |
| 2013 Q2 | 1.93 Billion JPY | -12.25% |
| 2013 Q3 | 1.99 Billion JPY | 2.95% |
| 2012 FY | -3.43 Billion JPY | -17.07% |
| 2012 Q4 | -3.43 Billion JPY | 20.64% |
| 2012 Q3 | -4.32 Billion JPY | 0.54% |
| 2012 Q2 | -4.35 Billion JPY | -58.89% |
| 2012 Q1 | -2.73 Billion JPY | 6.65% |
| 2011 FY | -2.93 Billion JPY | -43.87% |
| 2011 Q3 | -1.62 Billion JPY | -59.92% |
| 2011 Q1 | -1.99 Billion JPY | 2.23% |
| 2011 Q4 | -2.93 Billion JPY | -80.98% |
| 2011 Q2 | -1.01 Billion JPY | 49.15% |
| 2010 Q3 | -2.61 Billion JPY | 12.16% |
| 2010 Q1 | -1.34 Billion JPY | 18.29% |
| 2010 Q2 | -2.98 Billion JPY | -120.95% |
| 2010 FY | -2.03 Billion JPY | -23.48% |
| 2010 Q4 | -2.03 Billion JPY | 22.14% |
| 2009 Q2 | -2.41 Billion JPY | -23.92% |
| 2009 Q1 | -1.95 Billion JPY | 0.0% |
| 2009 Q4 | -1.65 Billion JPY | 0.0% |
| 2009 FY | -1.65 Billion JPY | 9.89% |
| 2008 FY | -1.83 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 1.22 Billion JPY | -2073.388% |
| Takeda Pharmaceutical Company Limited | 4385.95 Billion JPY | 99.393% |
| Sumitomo Pharma Co., Ltd. | 389.83 Billion JPY | 93.17% |
| Shionogi & Co., Ltd. | -346.47 Billion JPY | 107.684% |
| Wakamoto Pharmaceutical Co.,Ltd. | -3.56 Billion JPY | 847.001% |
| Nippon Shinyaku Co., Ltd. | -42.15 Billion JPY | 163.156% |
| Kaken Pharmaceutical Co., Ltd. | -61.47 Billion JPY | 143.309% |
| Eisai Co., Ltd. | -97.93 Billion JPY | 127.186% |
| Morishita Jintan Co., Ltd. | -667 Million JPY | 4091.604% |
| Hisamitsu Pharmaceutical Co., Inc. | -51.82 Billion JPY | 151.377% |
| Mochida Pharmaceutical Co., Ltd. | -32.92 Billion JPY | 180.872% |
| Fuso Pharmaceutical Industries,Ltd. | 7.6 Billion JPY | -250.224% |
| Nippon Chemiphar Co., Ltd. | 7.78 Billion JPY | -242.167% |
| Tsumura & Co. | 1.61 Billion JPY | -1548.545% |
| Kissei Pharmaceutical Co., Ltd. | -44.16 Billion JPY | 160.29% |
| Torii Pharmaceutical Co., Ltd. | -34.43 Billion JPY | 177.312% |
| Towa Pharmaceutical Co., Ltd. | 172.7 Billion JPY | 84.584% |
| Zeria Pharmaceutical Co., Ltd. | 28.98 Billion JPY | 8.135% |
| KYORIN Holdings, Inc. | 7.06 Billion JPY | -277.11% |
| Taiko Pharmaceutical Co.,Ltd. | 704 Million JPY | -3681.818% |
| Daito Pharmaceutical Co.,Ltd. | 5.99 Billion JPY | -344.326% |
| SymBio Pharmaceuticals Limited | -6.51 Billion JPY | 508.531% |
| MedRx Co., Ltd | -1.72 Billion JPY | 1647.907% |
| Mizuho Medy Co.,Ltd. | -8.71 Billion JPY | 405.445% |
| Solasia Pharma K.K. | -668 Million JPY | 4085.629% |
| Modalis Therapeutics Corporation | -1.47 Billion JPY | 1910.003% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | -7.25 Billion JPY | 467.076% |
| Sawai Group Holdings Co., Ltd. | 56.52 Billion JPY | 52.896% |
| Cyfuse Biomedical K.K. | -2.96 Billion JPY | 999.225% |
| Toho Holdings Co., Ltd. | -98.42 Billion JPY | 127.049% |
| Koa Shoji Holdings Co.,Ltd. | -11.12 Billion JPY | 339.218% |